|Product Name||Cat #||Size|
Anti-ENT1 (SLC29A1) Antibody
|ANT-051||1 x 50 µl|
Anti-ENT2 (SLC29A2) Antibody
|ANT-052||1 x 50 µl|
Anti-ENT3 (SLC29A3) Antibody
|ANT-053||1 x 50 µl|
Anti-Concentrative Nucleoside Transporter 1 (CNT1) Antibody
|ANT-061||1 x 50 µl|
Anti-Concentrative Nucleoside Transporter 2 (CNT2) Antibody
|ANT-062||1 x 50 µl|
- Lyophilized Powder Lyophilized Powder
This product is freeze dried. All water molecules have been removed.
- Antigen Incl. Control Antigen Included
This antibody is shipped with its antigen FREE of charge!
- Shipped at Room Temp. Shipped at Room Temp.
This lyophilized product is shipped at room temperature. Please see its certificate of analysis for further storage instructions.
Alomone Labs is pleased to offer the Nucleoside Transporter Antibody Explorer Kit (#AK-450). The Explorer Kit contains nucleoside transporter antibodies, ideal for screening purposes.
Nucleosides play other important roles beyond their nucleic acid synthesis building block role. For example, they are involved in energy metabolism; they serve as ligands of purinergic receptors and act as influential signaling molecules1. Being hydrophilic, nucleosides cannot simply diffuse across the plasma membrane in order to exert their various functions, but rather need to be physically transported via nucleoside transporters1,2.
Two different transporter families are responsible for transporting nucleosides across the plasma membrane: 1. The Concentrative Nucleoside Transporter proteins (CNT, SLC28 family), which consist of three members, CNT1-3, and act as Na+-dependent symporters1,3. 2. The Equilibrative Nucleoside Transporter proteins ENT1-4 (ENT, SLC29 family), which mediate a Na+-independent facilitated diffusion. Therefore, ENTs act as bidirectional carriers, responsible for the influx and efflux of substrates1.
There is no evidence that nucleoside transporters are directly involved in pathophysiologies, but they are clinically significant. For example, nucleoside transporters are responsible for the cellular uptake of a number of nucleoside-derived anticancer drugs1.
- Molina-Arcas, M. et al. (2009) Curr. Vasc. Pharmacol. 7, 426.
- Rose, J.B. and Coe, I.R. (2008) Physiology 23, 41.
- Baldwin, S.A. et al. (2004) Pflugers Arch. 447, 735.
- Gray, J.H. et al. (2004) Pflugers Arch. 447, 728.
- Ritzel, M.W. et al. (1998) Mol. Membr. Biol. 15, 203.
- Ritzel, M.W. et al. (2001) J. Biol. Chem. 276, 2914.
- Smith, K.M. et al. (2005) J. Biol. Chem. 280, 25436.
- Pennycooke, M. et al. (2001) Biochem. Biophys. Res. Commun. 280, 951.
- Felipe, A. et al. (1998) Biochem. J. 330 (Pt.2), 997.
- Valdes, R. et al. (2000) Gastroenterology 119, 1623.
- Anderson, C.M. et al. (1996) Brain Res. Mol. Brain Res. 42, 358.
- Guillen-Gomez, E. et al. (2004) J. Neurochem. 90, 883.